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Background: Ewing’s sarcoma (ES) is the second most common bone or soft-tissue sarcoma in childhood and
adolescence and features a high propensity to metastasize. The six-transmembrane epithelial antigen of the prostate 1
(STEAP1) is a membrane-bound mesenchymal stem cell marker highly expressed in ES. Here, we investigated the role
of STEAP1 as an immunohistological marker for outcome prediction in patients with ES.
Patients and methods: Membranous STEAP1 immunoreactivity was analyzed using immunohistochemistry in 114
primary pre-chemotherapy ES of patients diagnosed from 1983 to 2010 and compared with clinical parameters and
patient outcome. Median follow-up was 3.85 years (range 0.43–17.51).
Results: A total of 62.3% of the ES samples displayed detectable STEAP1 expression with predominant localization of
the protein at the plasma membrane. High membranous STEAP1 immunoreactivity was found in 53.5%, which
correlated with better overall survival (P = 0.021). Accordingly, no or low membranous STEAP1 expression was
identiﬁed as an independent risk factor in multivariate analysis (hazard ratio 2.65, P = 0.036).
Conclusion: High membranous STEAP1 expression predicts improved outcome and may help to deﬁne a speciﬁc
subgroup of ES patients, who might beneﬁt from adapted therapy regimens.
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introduction
Ewing’s sarcoma (ES) is a highly aggressive bone or soft-tissue
cancer mostly affecting children and young adolescents [1–4].
Even though multimodal treatments have led to remarkable
improvements in survival of patients with localized disease,
prognosis of patients with metastatic disease remains poor with
an event-free survival of <25% [4–7].
ES is characterized by EWS–ETS translocations [8] encoding
aberrant transcription factors that determine the complex and
highly malignant phenotype of this disease [9]. Although
different variants of EWS–ETS fusion proteins exist, they fail to
provide reliable biomarkers for individual risk stratiﬁcation
[10, 11]. Several trials proved the clinicopathological
parameters, tumor site, tumor volume, age at diagnosis,
responsiveness to chemotherapy, and sites of metastatic
disease, to have major prognostic value [10, 12, 13]. However,
the currently available biological markers for ES are very
limited [12, 14, 15]. Nevertheless, the discovery of novel
prognostic and/or predictive biomarkers would potentially lead
to a better understanding of tumor heterogeneity, enable
individual risk stratiﬁcation, and might help to guide targeted
therapy [16–19].
We previously identiﬁed an expression signature comprising
∼40 genes that are highly overexpressed in ES compared with
normal tissues and that might constitute promising candidates
for risk prediction and targeted therapy [9, 20]. Among them,
we identiﬁed the six-transmembrane epithelial antigen of the
prostate 1 (STEAP1), which is a membrane-bound channel
protein possibly involved in transmembrane electron transfer
[21, 22]. Apart from low amounts in prostate and urothelium,†These authors contributed equally to this work.
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STEAP1 is virtually not expressed in normal tissues [23, 24].
In contrast, STEAP1 is strongly overexpressed in many cancers
including prostate, breast, and bladder carcinoma as well as ES
[23–25]. STEAP1 messenger RNA (mRNA) circulates in
peripheral blood of cancer patients [26] and its detection in
bone marrow is indicative for occult residual tumor cells in
patients with ES [27]. Moreover, STEAP1 was found to be a
bona ﬁde marker for human mesenchymal stem cells [28]
lending support to the hypothesis of a mesenchymal origin of
ES [29].
In addition, we recently showed that STEAP1 overexpression
increases the invasive properties and intracellular levels of
reactive oxygen species (ROS) of ES cells [24]. However, the
diagnostic potential of STEAP1 for ES remained
undetermined.
In the current study, we investigated the value of STEAP1 as
an immunohistological marker for outcome prediction of
patients with ES. We provide evidence that high membranous
STEAP1 expression is associated with improved overall survival
(OS). Moreover, high membranous STEAP1 immunoreactivity
showed a trend toward a better histological tumor response to
chemotherapy and, conversely, STEAP1-silenced ES cells were
more resistant to chemotherapy in vitro. These data unravel a
hitherto unanticipated role of STEAP1 as a promising
independent biomarker for outcome prediction of ES.
materials and methods
study population, ES tissue samples, and tissue
microarray
The Technische Universität München and the Universities of Basel,
Düsseldorf, and Münster approved the current study. A total of 114
archival parafﬁn-embedded primary ES samples before treatment with
conﬁrmed histological diagnosis (reference pathology) were obtained from
the Departments of Pathology of the Technische Universität München and
the University of Düsseldorf as well as from the Bone Tumor Reference
Center at the Institute of Pathology of the University of Basel.
Representative formalin-ﬁxed, parafﬁn-embedded tumor blocks were
selected for either tissue microarray (TMA) construction at the Department
of Pathology of the University of Düsseldorf (66 samples) or open
procedures at the Departments of Pathology of the Technische Universität
München (6 samples) and the University of Basel (42 samples). Each TMA
slide contained reference tissues of ES xenografts with known STEAP1
expression as internal controls (see supplemental Methods, available at
Annals of Oncology online).
Pertinent clinical data of patients were compiled from two sources:
ﬁrst, the Ewing trial center of the University Hospital Münster (93
patients enrolled in the CESS 81, CESS 86, EICESS 92, or EURO-E.W.
I.N.G. 99 trials) and second, the Department of Pathology of the
University of Basel (21 patients). Informed consent was obtained from
all patients and/or their legal guardians. The study population included
60 males and 54 females with a median age of 16.9 years (range 0.6–
59.8 years).
immunohistochemistry and evaluation of STEAP1
immunoreactivity
Immunohistochemistry (IHC) analyses were done on formalin-ﬁxed,
parafﬁn-embedded, pre-chemotherapy primary tumors. All tissue slides
were collected at the Department of Pathology of the Technische
Universität München for immediate IHC staining. For IHC, 4-μm sections
were cut and stained by an automated immunostainer with an iView DAB
detection kit (Ventana Medical System, Tucson, AZ) according to the
company’s protocol. The following primary antibody was used: polyclonal
rabbit anti-STEAP1 (1:50; H-105, sc-25514, Santa Cruz). Antigen retrieval
was carried out by microwave treatment in Dako target retrieval solution,
citrate, pH 6.0. Sections were counterstained with hematoxylin. For internal
controls, we used tumors of xenografted ES cell lines with known STEAP1
mRNA and protein expression levels (see supplemental Methods and
Figure S1, available at Annals of Oncology online). Speciﬁcity of the
STEAP1 antibody was assessed previously by others [30, 31] and reassessed
by us using immunoblot and indirect immunoﬂuorescence, as previously
described [32, 33] (see supplemental Methods and Figure S1, available at
Annals of Oncology online). These control experiments further conﬁrmed
the speciﬁcity of the used STEAP1 antibody, in agreement with published
ﬁndings on the STEAP1 protein [23, 24, 34]. Semi-quantitative evaluation
of STEAP1 immunostaining was carried out in a blinded manner by a
pathologist (IE) and two scientist experienced in histopathology (PS-B,
MA) after having examined at least three high-power ﬁelds (40×) of one
section for each sample. The intensity of membranous STEAP1
immunoreactivity was determined as grade 0 = none, grade 1 = faint, grade
2 =moderate, and grade 3 = strong (Figure 1). Intensity scoring was
independently recorded and in case of disagreement determined by
consensus. For better statistical discrimination, samples were classiﬁed into
two groups as previously described [32, 35]: samples with grade 0 and 1
were classiﬁed as STEAP1 low and those with grade 2 and 3 as STEAP1
high.
Figure 1. Examples of heterogeneous membranous six-transmembrane
epithelial antigen of the prostate 1 (STEAP1) immunoreactivity in Ewing’s
sarcoma (ES): All samples depicted were located on the same tissue
microarray slide and stained simultaneously by an automated
immunostainer (see ‘materials and methods’ section). Membranous
STEAP1 immunoreactivity (brown color) was scored according to reference
ES with known STEAP1 expression levels, with grade 3 = strong (A), grade
2 =moderate (B), grade 1 = faint (C), and grade 0 = no immunoreactivity
(D). Grades 3 and 2 were classiﬁed as STEAP1 high and grades 1 and 0 as
STEAP1 low. Scale bars = 20 μm for overview and 80 μm for detail images.
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statistical analyses
Statistical analyses were carried out with SPSS 19 (IBM Corporation,
Armonk, NY) and SAS 9.2 (SAS Institute, Cary, NC). OS was estimated by
the Kaplan–Meier method. OS time was deﬁned as the interval between the
date of diagnosis and the date of last follow-up or death. Living patients
were censored at the date of most recent consultation. Group comparisons
were calculated by log-rank test. Multivariate analyses were carried out by
applying the Cox proportional hazard method. Differences in proportions
between groups were evaluated by chi-square or Fisher’s exact test.
Signiﬁcance level was set at P < 0.05 for two-sided testing. No alpha
corrections were carried out for multiple testing. Outcome was analyzed on
an exploratory basis.
results
STEAP1 is expressed in the majority of ES and
mainly locates to plasma membranes
We ﬁrst aimed to deﬁne the expression pattern of STEAP1 in
ES. Of the 114 ES available for IHC, 71 displayed detectable
membranous STEAP1 immunoreactivity (62.3%, grades 1–3).
Examples of the differential membranous STEAP1
immunoreactivity are given in Figure 1. A total of 53.5% (n =
61) of the ES were scored as membranous STEAP1 high and
46.5% (n = 53) as membranous STEAP1 low; 24.6% (28 of
114) of the cases showed maximum membranous STEAP1
expression (grade 3; see Figure 1). In agreement with previous
ﬁndings in breast, bladder, and prostate carcinoma [21, 23, 25],
we noted a predominant plasma membranous localization of
STEAP1 without deﬁned apical or basal accentuation and
mostly without cytoplasmic STEAP1 immunoreactivity. Only a
few ES samples showed a faint to moderate cytoplasmic
STEAP1 staining.
membranous STEAP1 expression and OS
We next aimed to determine whether membranous STEAP1
expression correlates with outcome of ES patients. Patient
characteristics are given in Table 1. Univariate analysis on the
predictive value of membranous STEAP1 immunoreactivity
showed a lower survival rate in patients with ES classiﬁed as
membranous STEAP1-low (5-year OS = 0.57; n = 53) when
compared with membranous STEAP1-high cases (5-year OS =
0.79; n = 61) (P = 0.021) (Figure 2).
multivariate analysis
We next analyzed the impact of risk stratiﬁcation in patients
with membranous STEAP1-high ES compared with patients
with membranous STEAP1-low ES to rule out a possible bias
by favorable risk factor patterns in STEAP1-high cases. The
multivariate analysis served to identify underlying factors that
could inﬂuence prognosis. We included the known prognostic
factors metastatic stage at diagnosis (M0, M1, M2), site (axial
versus nonaxial), and age (<15 versus ≥15 years) [7, 12, 13] in
the multivariate analysis. Eighty-three patients (72.8%) had
localized disease (M0), 20 patients (17.5%) had pulmonary
metastases (M1), and 11 patients (9.6%) had disseminated
disease including other metastases than in lungs (M2). Sixty-
six patients (57.9%) presented with an axial site ES and 48
patients (42.1%) with a non-axial site ES. Forty-six patients
(40.4%) were aged <15 years, and 68 patients (59.6%) were
aged >15 years at time of diagnosis.
The major risk factor was metastatic disease at diagnosis
[M0: hazard ratio (HR) = 1.00; M1: HR = 2.19; M2: HR = 4.38;
P = 0.002]. Membranous STEAP1-low expression (HR = 1.76;
P = 0.094), age (>15 years, HR = 1.69; P = 0.135), and primary
axial tumor site (HR 1.30; P = 0.435) showed only a tendency
or no major impact on survival (n = 114; Table 2).
In a second step, we analyzed the major group of patients
with localized disease (M0; n = 83). Here, membranous
STEAP1-low expression (HR = 2.59; P = 0.036) and age (>15
years; HR = 3.39; P = 0.030) were major risk factors concerning
survival in relation to primary axial tumor site (HR 1.76; P =
0.218) (Table 3), which most likely still only showed a
Table 1. Patient characteristics (n = 114)
Variable Label n (%)
Sex Male 60 (52.6)
Female 54 (47.4)
Age at diagnosis <15 years 46 (40.4)
≥15 years 68 (59.6)
Risk group M0 (no metastases) 83 (72.8)
M1 (lung metastases) 20 (17.5)
M2 (other ± lung
metastases)
11 (9.7)
Site Axial 66 (57.9)
Non-axial 48 (42.1)
Tumor volumea <200 ml 55 (71.4)
≥200 ml 22 (28.6)
Histological responsea Good (<10% viable cells) 46 (78.0)
Poor (≥10% viable cells) 13 (22.0)
Membranous six-
transmembrane
epithelial antigen of the
prostate 1 expression
How 53 (46.5)
High 61 (53.5)
aThese parameters relate to subsets of the study population.
Figure 2. Six-transmembrane epithelial antigen of the prostate 1
(STEAP1) expression correlates with overall survival (OS): Kaplan–Meier
estimates for OS probability for membranous STEAP1 expression (n = 114,
P = 0.021). Log-rank test.
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tendency on survival due to the limited size of our patient
cohort.
Tumor volume: A tumor volume categorization (<200 versus
≥200 ml) was only available in 77 patients. Fifty-ﬁve patients
(71.4%) had a tumor volume <200 ml and 22 patients (28.6%)
had a tumor volume >200 ml. Multivariate analysis in this
subcohort of 77 patients adding tumor volume as known
prognostic factor to the other established prognostic factors
described above (metastatic disease at diagnosis, age >15 years,
and primary axial tumor site [7, 12, 13]) conﬁrmed metastatic
disease at diagnosis (P = 0.002) and membranous STEAP1-low
expression (HR = 2.65; P = 0.036) as major risk factors.
association of STEAP1 expression with histological
response to chemotherapy
Since high membranous STEAP1 immunoreactivity correlated
with improved OS, we tested whether this observation is
associated with a better response to treatment as estimated by
Salzer–Kuntschik tumor regression states [36]. For 59 patients
(51.8%), data were available for histological response following
induction chemotherapy without concurrent early
radiotherapy. Forty-six patients (78%) showed a good
histological response (<10% viable tumor cells) and 13 patients
(22%) a poor histological response (≥10% viable tumor cells);
80.6% of the patients with membranous STEAP1-high
expression showed a good histological response compared with
73.9% of the patients with membranous STEAP1-low
expression (P = 0.748) (Table 4). To test whether differential
STEAP1 expression may indeed alter response to
chemotherapy in vitro, we transiently knocked down STEAP1
in cultured ES cells by RNA interference and assessed their
rates of necrosis by ﬂow cytometry. STEAP1-silenced ES cells
treated with either doxorubicin or etoposide for 24 h exhibited
lower rates of necrosis compared with ES cells with high
STEAP1 expression (P < 0.01; t-test, n = 4) (Figure S2),
indicating that low STEAP1 expression may confer ES cells
with a more resistant phenotype to chemotherapy.
discussion
Combined modality treatment is crucial for successful therapy
of patients with ES [7]. So far, various studies have identiﬁed
metastatic state, tumor volume, tumor site, age, sex, and
histological response to chemotherapy as important risk
factors, with primary metastasis as the most unfavorable one
[7, 12, 13, 37]. Although there is agreement that clinical
management will beneﬁt from biological markers that can
guide therapeutic decisions [12], apart from the proliferation
marker Ki67 [38, 39], there are no bona ﬁde
immunohistological markers available predicting outcome of
patients with ES [12, 15].
This is, to the best of our knowledge, the ﬁrst report
evaluating the potential of STEAP1 for outcome prediction in
ES. Regarding independent risk factors in our series, high
membranous STEAP1 expression had a strong impact on OS
in multivariate analysis.
Moreover, membranous STEAP1-high immunoreactivity
showed a trend toward a better tumor response compared with
membranous STEAP1-low immunoreactivity as estimated by
Salzer–Kuntschik regression states. Even though this
subsample tendency has to be validated in a larger cohort, it is
noteworthy that high STEAP1 expression improves response of
ES cells to chemotherapy in vitro. Hence, it is tempting to
speculate that STEAP1 may exert a biological function that
sensitizes ES to drugs such as doxorubicin and etoposide,
which are essential components of current ES treatment
protocols [40].
On the molecular level, STEAP1 is a homologue of NADPH
oxidases [41, 42], which are involved in cellular ROS
production and frequently overexpressed in cancer [43, 44].
Consistent with this notion, we recently demonstrated that
STEAP1 overexpression in ES cells increases their intracellular
ROS levels [24]. Similar observations were obtained by Pan
et al. in thyroid epithelial cells [45] Pharmacologically, multiple
studies demonstrated that certain chemotherapeutics like
Table 2. Summary of results of the multivariate analysis in all patients
(n = 114)
Variable Label Risk ratio
(95% CI)
P
Risk group M0 (no metastases) 1 0.002
M1 (lung metastases) 2.19 (1.04–4.61) 0.039
M2 (other ± lung
metastases)
4.38 (1.83–10.5) 0.001
Membranous
STEAP1 expression
Low 1.78 (0.91–3.48) 0.094
Age ≥15 years 1.69 (0.85–3.37) 0.135
Site Axial 1.30 (0.68–2.48) 0.435
STEAP1, six-transmembrane epithelial antigen of the prostate 1 and CI,
conﬁdence interval.
Table 3. Summary of results of the multivariate analysis in patients with
localized disease (n = 83)
Variable Label Risk ratio
(95% CI)
P
Membranous STEAP1
expression
Low 2.59 (1.07–6.29) 0.036
Age ≥15 years 3.39 (1.13–10.2) 0.030
Site Axial 1.76 (0.72–4.31) 0.218
STEAP1, six-transmembrane epithelial antigen of the prostate 1 and CI,
conﬁdence interval.
Table 4. Summary of results of correlation of membranous STEAP1
immunoreactivity with tumor regression grade (n = 59)
Histological response
Good Poor P
Membranous STEAP1 expression Low 17 (73.9%) 6 (26.1%)
High 29 (80.6%) 7 (19.4%) 0.748
STEAP1, six-transmembrane epithelial antigen of the prostate 1.
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doxorubicin and etoposide become more potent at increased
intracellular ROS levels [46, 47]. Moreover, radiotherapy is
known to be more effective in combination with ROS-
generating radiosensitizers [47, 48]. Thus, the apparent survival
beneﬁt seen in membranous STEAP1-high ES patients may be
caused by elevated intracellular ROS levels of the ES cells,
which might sensitize them to radiochemotherapy.
As outlined above, metastasis of ES is the most adverse
clinical parameter indicative for dismal prognosis with a 5-
year relapse-free survival of ∼21% compared with 55% in
patients with localized disease. Strikingly, the observed
survival beneﬁt of membranous STEAP1-high compared
with membranous STEAP1-low immunoreactivity is
similarly strong like the dramatic difference in survival
indicated by localized versus metastatic disease. Hence, our
data suggest that high membranous STEAP1 expression
may be a property of an independent risk group of ES
patients, who speciﬁcally might beneﬁt from adapted radio-
chemotherapy protocols.
Despite we are fully aware of the retrospective nature of this
study and its associated limitations, STEAP1 may constitute a
promising new biomarker for outcome prediction of ES
patients, which is readily available due to standardized
assessment by immunohistochemistry. Therefore, we strongly
recommend to validate this observation in prospective studies
and to experimentally elucidate the precise molecular role of
STEAP1 in ES.
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